Volume | 2,846,383 |
|
|||||
News | - | ||||||
Day High | 56.105 | Low High |
|||||
Day Low | 55.75 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Catalent Inc | CTLT | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
55.88 | 55.75 | 56.105 | 55.92 | 55.80 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
15,250 | 2,846,383 | $ 55.91 | $ 159,133,924 | - | 31.45 - 60.20 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:32:52 | priorref | 95,000 | $ 55.92 | USD |
Catalent (CTLT) Options Flow Summary
Catalent Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
10.1B | 180.74M | - | 4.26B | -256M | -1.42 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Catalent News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CTLT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 55.91 | 56.32 | 55.42 | 55.87 | 1,780,393 | 0.01 | 0.02% |
1 Month | 56.41 | 57.1999 | 55.42 | 56.31 | 1,621,052 | -0.49 | -0.87% |
3 Months | 52.46 | 60.20 | 52.03 | 57.29 | 2,817,077 | 3.46 | 6.60% |
6 Months | 39.32 | 60.20 | 31.8001 | 49.60 | 2,489,183 | 16.60 | 42.22% |
1 Year | 42.17 | 60.20 | 31.45 | 45.48 | 2,912,833 | 13.75 | 32.61% |
3 Years | 115.00 | 142.64 | 31.45 | 64.09 | 2,045,911 | -59.08 | -51.37% |
5 Years | 44.62 | 142.64 | 31.04 | 67.09 | 1,664,439 | 11.30 | 25.32% |
Catalent Description
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents. |